TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

被引：41
|
作者：
Gram, Dorte X. [1 ]
Holst, Jens J. [2 ]
Szallasi, Arpad [3 ]
机构：
[1] Pila Pharma, Malmo, Sweden
[2] Univ Copenhagen, Panum Inst, Copenhagen, Denmark
[3] Baptist Med Ctr, Jacksonville, FL USA
来源：
TRENDS IN MOLECULAR MEDICINE | 2017年 / 23卷 / 11期
关键词：
GENE-RELATED PEPTIDE; SENSORY NERVE DESENSITIZATION; SUBSTANCE-P; INSULIN-SECRETION; GLUCOSE-TOLERANCE; PERIPHERAL NEUROPATHY; INFLAMMATORY MARKERS; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTORS; ISLET INFLAMMATION;
D O I：
10.1016/j.molmed.2017.09.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.
引用
收藏
页码：1002 / 1013
页数：12
相关论文
共 50 条
  • [21] Role of the Transient Receptor Potential Vanilloid Type 1 (TRPV1) in the Regulation of Nitric Oxide Release in Wistar Rat Aorta
    Varela-Lopez, Elvira
    del Valle-Mondragon, Leonardo
    Castrejon-Tellez, Vicente
    Perez-Torres, Israel
    Arenas, Araceli Paez
    Rojas, Felipe Masso
    Guarner-Lans, Veronica
    Vargas-Gonzalez, Alvaro
    Pastelin-Hernandez, Gustavo
    Torres-Narvaez, Juan Carlos
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021
  • [22] Stimulating TRPV1 externalization and synthesis in dorsal root ganglion neurons contributes to PGE2 potentiation of TRPV1 activity and nociceptor sensitization
    Ma, W.
    St-Jacques, B.
    Rudakou, U.
    Kim, Y. N.
    EUROPEAN JOURNAL OF PAIN, 2017, 21 (04) : 575 - 593
  • [23] Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes
    Burant, Charles F.
    DIABETES CARE, 2013, 36 : S175 - S179
  • [24] The potential of TRPV1 agonists for treating ischemia/reperfusion-induced renal injuries
    Rayamajhi, Supratik
    Contractor, Tahmeed
    Wang, Donna H.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (09) : 963 - 970
  • [25] DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes
    Ronn, Tina
    Ling, Charlotte
    EPIGENOMICS, 2015, 7 (03) : 451 - 460
  • [26] Structural Aspects of Gut Peptides with Therapeutic Potential for Type 2 Diabetes
    Hewage, Chandralal M.
    Venneti, Kalyana C.
    CHEMMEDCHEM, 2013, 8 (04) : 560 - 567
  • [27] Can NK cells be a therapeutic target in human diseases? Can NK cells be a therapeutic target in human type 1 diabetes?
    Dotta, Francesco
    Fondelli, Cecilia
    Falorni, Alberto
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (11) : 2961 - 2963
  • [28] Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus
    Kabir, Md Tanvir
    Mitu, Jannatul Ferdous
    Akter, Raushanara
    Akhtar, Muhammad Furqan
    Saleem, Ammara
    Al-Harrasi, Ahmed
    Bhatia, Saurabh
    Rahman, Md Sohanur
    Damiri, Fouad
    Berrada, Mohammed
    Rahman, Md Habibur
    ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2022, 29 (31) : 46385 - 46404
  • [29] Remote ischemic conditioning: A potential therapeutic strategy of type 2 diabetes
    Liu, Jie
    Sun, Xin
    Jin, Hang
    Yan, Xiu-Li
    Huang, Shuo
    Guo, Zhen-Ni
    Yang, Yi
    MEDICAL HYPOTHESES, 2021, 146
  • [30] TRP Channels as Targets for Therapeutic Intervention in Obesity: Focus on TRPV1 and TRPM5
    Palmer, R. Kyle
    Lunn, Charles A.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (03) : 247 - 257
12345